The VistaShares Target 15™ Berkshire Select Income ETF (OMAH) is rated Buy for its unique strategy that targets a 15% annual distribution rate through covered call and options on blue-chip stocks, mostly non-dividend-paying. The fund focuses on income generation with monthly payouts and has recently shifted its portfolio by reducing technology exposure and increasing financial and communication sectors. This active management approach positions OMAH well for a market rotation from growth to value stocks, with expected rising volatility supporting stable premium income and distributions. The ETF appeals to income-focused investors seeking high yield beyond traditional dividends, especially in a retirement income context.
The VistaShares Target 15™ Berkshire Select Income ETF (OMAH) is highlighted here with Pluang's market data for context. For readers following US stocks on Pluang as of Oct 14, 2026 21:41 WIB: out of 150 priced stocks, 38 rose and 111 fell. Notable movers include FCEL at USD 14.76 with a 1-day change of -4.74% and a strong 80% buy order activity, HPE at USD 65.58 down 4.68% with 89% sell orders, and MRVL at USD 256.69 down 4.48% with balanced buy/sell activity.
Jefferies has maintained a Buy rating on Big Yellow Group despite recent stock declines, citing the company's strong fundamentals including freehold properties and solid cash flows. Activist investor Ancora, holding over 4% of shares, is pushing Big ...
Fastenal reported strong Q3 2026 earnings, beating analyst expectations with EPS of $0.35 and revenue of $2.46 billion. The company saw a 20% rise in net income to $401.6 million and a 15.5% increase in revenue driven by robust manufacturing demand, ...
Remittix announced the public launch of its RTX token on November 24, 2026, marking the end of its presale phase which raised over $32 million from 40,000 participants. The project is testing its PayFi platform, which enables crypto-to-fiat and fiat-...
The global microbiology testing market is projected to grow rapidly at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching a market size of $13.7 billion by 2034. This growth is driven by the rising prevalence of infe...
H.C. Wainwright raised its price target for Alector from $5.00 to $8.00, maintaining a Buy rating due to progress in its neurodegenerative disease pipeline. Alector develops treatments for Alzheimer's and Parkinson's using its Brain Carrier platform ...
